Inclisiran sodium

英克司兰钠

Report date: 2026/04/03 20:03:44
NMEFirst In Class

Base Information

Drug NameInclisiran sodium
Drug Alias NameinclisiranLeqvio乐可为ALN-60212PCSK9si +[8] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitorsRNA interference
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaHomozygous familial hypercholesterolemiaHypercholesterolemia +[18] 
Global Approved IndicationsHeterozygous familial hypercholesterolemiaHypercholesterolemiaDyslipidemias +[4] 
Approved Indications in ChinaHypercholesterolemiaDyslipidemias
Original Approved Country/TerritoryEU
Original Approved Date2020/12/09
Country/TerritoryCzechiaBelgiumBulgaria +[60] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAlnylam Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAlcami Carolinas CorporationCorden PharmaUniversity Of Oxford +[11] 
Inactive CompaniesIcahn School Of Medicine At Mount SinaiAlnylam Pharmaceuticals IncAlcami Carolinas Corp +[4] 
Active IndicationsHeterozygous familial hypercholesterolemiaHomozygous familial hypercholesterolemiaHypercholesterolemia +[15] 
Inactive IndicationsDiabetes MellitusCardiovascular DiseasesRenal Insufficiency

Other Information

ATC CodeC10AX
Related LinksWikipediaDrugBankKEGG